Abstract: PURPOSE: Tumor hypoxia activates hypoxia-inducible factors (Hifs), which induce a range of malignant changes including vascular abnormalities. Here, we determine whether inhibition of the hypoxic tumor response through myo-inositol trispyrophosphate (ITPP), a compound with antihypoxic properties, is able to cause prolonged vascular normalization that can be exploited to improve standardof-care treatment. EXPERIMENTAL DESIGN: We tested ITPP on two syngeneic orthotopic mouse models of lethal colorectal cancer liver metastasis. Tumors were monitored by MRI and analyzed for the hypoxic response and their malignant potential. A Hif activator and in vitro assays were used to define the working mode of ITPP. Hypoxic response and vasculature were re-evaluated 4 weeks after treatment. Finally, we determined survival following ITPP monotherapy, FOLFOX monotherapy, FOLFOX plus Vegf antibody, and FOLFOX plus ITPP, both overlapping and sequential. RESULTS: ITPP reduced tumor load, efficiently inhibited the hypoxic response, and improved survival. These effects were lost when mice were pretreated with a Hif activator. Its immediate effects on the hypoxic response, including an apparent normalization of tumor vasculature, persisted for at least 4 weeks after treatment cessation. Compared with FOLFOX alone, Vegf antibody combined with FOLFOX prolonged survival by <30%, whereas ITPP combined with FOLFOX extended survival by >140%, regardless of whether FOLFOX was given in overlap or after ITPP exposure. CONCLUSIONS: Our findings reveal a truly antihypoxic mechanism for ITPP and demonstrate the capacity of this nontoxic compound to potentiate the efficacy of existing anticancer treatment in a way amenable to clinical translation. Clin Cancer Res; 22(23); 5887-97. DOI: https://doi.org/10.1158/1078-0432. Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-125980 Accepted Version Originally published at: Limani, P; Linecker, M; Kachaylo, E; Tschuor, C; Kron, P; Schlegel, A; Ungethuem, U; Jang, J H; Georgiopoulou, S; Claude Nicolau, C; Lehn, J-M; Graf, R; Humar, B; Clavien, P-A (2016). Antihypoxic potentiation of standard therapy for experimental colorectal liver metastasis through myo-inositol trispyrophosphate. Clinical Cancer Research, 22 (23) Results. ITPP reduced tumor load, efficiently inhibited the hypoxic response, and improved survival. These effects were lost when mice were pretreated with a Hif activator. Its immediate effects on the hypoxic response, including an apparent normalization of tumor vasculature, persisted for at least four weeks after treatment cessation. Compared to FOLFOX alone, Vegf antibody combined with FOLFOX prolonged survival by <30%, whereas ITPP combined with FOLFOX extended survival by >140%, regardless of whether FOLFOX was given in overlap or after ITPP exposure.
Translational relevance
Besides the promotion of malignant behavior, tumor hypoxia induces brittle vasculature that impedes the efficient delivery of chemotherapeutic agents. Inositol trispyrophosphate (ITPP) is a novel antihypoxic compound known to inhibit the hypoxic tumor response and to improve drug delivery if given concomitantly. More so, ITPP lacks significant toxicity and hence may effectively be used in the clinic for the improvement of existing treatments. Here, we provide important, but currently lacking data to inform future phase II/III trials on ITPP. We illustrate the main working mode of ITPP, show that the antihypoxic/vascular effects of ITPP are sustained, and demonstrate the superiority of ITPP in potentiating subsequent chemotherapy effects. Acting as a direct inhibitor of tumor hypoxia, ITPP treatment generates a time window that can be exploited to enhance existing chemotherapy regimens. A phase Ib/IIa trial is currently assessing the safety of ITPP in cancer patients.
Introduction
Tumor hypoxia activates the hypoxia-inducible factors (Hifs), which induce an adaptive response associated with an array of processes that foster tumor progression (1) (2) (3) (4) . Most famous is the angiogenic switch, leading to the formation of immature, leaky vessels that however cannot re-install normoxia but instead enhance the spread of disease (5) . Vascular normalization -the reversal to a more physiological network of mature and tight vessels -is a goal aspired by modern therapies, particularly because it also promotes the delivery and efficacy of anticancer compounds (5) . However, hypoxia drives many other processes, including changes in energy metabolism (Warburg effect), chronic inflammation, suppression of adaptive immunity, invasive behavior, or an increased tumorigenic potential (6) (7) (8) (9) (10) . Considering this complexity, the arguably simplest approach to normalize vessels and combat malignant behavior is the targeting of hypoxia per se.
Myo-inositol trispyrophosphate (ITPP) is a novel molecule that combines the necessary
features for the successful treatment of tumor hypoxia (11) . Acting as an allosteric effector of hemoglobin, ITPP increases dissociation of O 2 from heme particularly under low pO 2 , creating antihypoxic potency (11) . Additionally, its uptake seems to be tissue-specific towards erythrocytes (12) . More so, ITPP does display little, if any, in vivo toxicity, neither in animals (13-16) nor humans (http://normoxys.com/clinical-trial-results/). In preclinical studies, ITPP markedly improved outcomes in hepatoma, colorectal cancer (CRC), breast cancer, melanoma, and pancreatic cancer (13) (14) (15) (16) . Combined evidence from these studies indicates ITPP restores tumor normoxia, downregulates Hif/Vegf, and inhibits processes associated with the hypoxic response. Notably, clear signs of vascular normalization were likewise reported. Owing to the improvements in vessel structure, ITPP strongly potentiated the effects of gemcitabine in a syngeneic model of pancreatic cancer (15, 16) .
Despite these impressive effects, several questions remain open before exploring ITPP in human cancer. Although the working mode of ITPP seemingly relies on the regain of tumor normoxia and the subsequent stalling of the hypoxic response, a formal prove for this is lacking and direct effects on cancer cells remain possible (15, 16) . The potentiation of cytotoxic chemotherapy through ITPP was shown in the setting of concomitant application (15, 16) . In clinical practice however, sequential (chemotherapy follows ITPP treatment) rather than concomitant application would be more feasible both in terms of ethical concerns and toxicity control. Likewise, how the combination of ITPP with chemotherapy will perform against current combination approaches that consider vascular normalization (i.e. anti-angiogenic therapy) is unknown.
Here, we tested ITPP on two syngeneic orthotopic mouse models of CRC liver metastasis, the most frequent cause of death due to CRC (17) . Our experiments were designed to i) clarify the working mode of ITPP, to ii) establish a time window associated with vascular normalization through ITPP, and to iii) estimate the clinical efficacy of ITPP-enhanced chemotherapy by comparing with the current standard FOLFOX plus neutralizing Vegf antibody.
Methods

Animals
All animal experiments were in accord with Swiss Federal Animal Regulations and approved by the Veterinary Office of Zurich. Male mice (C57Bl/6 and BALB/c, from Harlan.
Itingen, Switzerland) aged 10-12 weeks were kept on a 12-hour day/night cycle with free access to food and water.
Animal Procedures, Treatment, and MRI Imaging
Selective portal vein injection was used for the generation of CRC liver metastasis, with concurrent clamping of distal liver lobes leading to tumor development restricted to the right and caudate lobes. Thereby, survival mainly depends on the cancer development within affected lobes (manuscript under revision). ITPP was synthesized as previously described (11) and administered as a solution containing calcium chloride to balance its chelating effects (13) .
ITPP was injected i.v. five times every 48h in a volume of 100 µl at 500mg/kg (Fig. 1A) .
Controls received saline. DMOG (BML-EI347-0050, Enzo Life Science, Farmingdale, New York; 40 mg/kg in 100 µl saline) was i.v. injected 4h before every ITPP injection (18) . FOLFOX (6 mg/kg oxaliplatin, followed 2h later by 90 mg/kg folinic acid and 50 mg/kg 5-fluorouracil, Sigma-Aldrich, Dorset, UK) was given 5x every other day either alone for monotherpay (akin to ITPP, Fig. 1A ), or 24h following ITPP administration (overlapping mode) or 24h after the last ITPP dose (sequential mode) for combination therapy (19) . Controls received saline. Anti-Vegf antibody or control IgG (4 µg/kg, R&D Systems, Abingdon UK) were injected i.v. concomitant with FOLFOX as described (20) . MRI was performed on a Bruker Biospin 4.7 Tesla imager (Ettlingen, Germany) at the day 7, 17, 45, or at time of death in the survival studies.
Blood oxygen saturation
Oxygen dissociation curves (P50 values) were determined with a HEMOX Analyzer (TCS Scientific, New Hope, PA). The percentage of O 2 hemoglobin saturation was continuously recorded in 50 μL blood mixed with 3 mL Hemox buffer and 10 μL anti-foaming agent equilibrated at 37°C. Chart software (AD Instruments, Colorado Springs, USA) was used for analysis (13) .
Cell culture and ex vivo experiments
Syngeneic CRC cells MC-38 (C57Bl/6 background, a kind gift from Carole Bourquin) and CT-26 (BALB/c background, LGC Promochem, Molsheim, France) were cultured as reported (21) . Freshly resected tumors were sequentially minced through a 100µm and a 30µm mesh (BD Falcon TM , Franklin Lakes, NJ) into single cells. Invasion assays were performed using 8µm pore cell culture inserts and Matrigel (BD Falcon TM ) as described (22) . For s.c. injections, 100
µl of single cell preparation from resected tumors at 5x10 6 cells/ml in PBS were used. Glucose and lactate levels were determined with a Fuji Dri-Chemi 4000i (Fujifilm Corporation, Tokyo, Japan). All in vitro experiments were performed in triplicates.
Histological assessment
Hematoxylin-Eosine staining was performed on 3µm archived liver sections. For immunohistochemistry, antigens were retrieved by boiling in citrate buffer. Secondary detection was done using the Ventana Discovery automated staining system and the iView DAB kit (Ventana Medical Systems, Tucson, AZ). See Supplements for primary antibodies.
Real-Time Polymerase Chain Reaction, Western blots, ELISA
qRT-PCR and immunoblots were performed as described (20) . See Supplements for further information.
Statistical Analysis
At least six animals/group were analyzed unless specified otherwise. Differences between the groups were assessed by a 2-tailed t test assuming unequal variance, or by one-way analysis of variance where applicable. Statistical significance was set at p<0.05, with data presented as means and 95% confidence intervals. Prism 5.0 (GraphPad, San Diego, CA) software was used.
Results
Impact of ITPP on tumor development
The impact of ITPP was tested on two syngeneic orthotopic models of CRC liver metastasis (MC-38 and CT-26 CRC cells injected into the portal vein of C57BL/6 and BALB/c mice, respectively). These models feature tumors restricted to the right and caudate liver lobes, with survival largely dependent on the intralobular tumor development (manuscript under revision).
ITPP treatment ( Supplementary Fig. 1A ) was started after tumor diagnosis by MRI at day 7
and was repeated five times every other day ( 
Impact of ITPP on the hypoxic tumor response
To demonstrate inhibition of the hypoxic response by ITPP, we assessed a series of markers related to hypoxia-driven processes. Overall, ITPP-treatment was associated with the inhibition of the Warburg effect (a shift from glycolysis to -oxidation, Fig. 2A , Supplementary   Fig. 3A) , with reduced inflammation, and the increased influx of immune cells (Fig. 2B,   Supplementary Fig. 3B ). Increased macrophage infiltration was associated with M1 polarization marker expression, consistent with an anticancerous phenotype (23) . Additionally, we observed 
Dependency of ITPP action on hypoxia-inducible factors
ITPP may inhibit the hypoxic response via Hif downregulation. If so, exogenous activation of Hifs should counteract its effects. Tumor-bearing mice (MC-38/B6) were injected with ITPP or saline and co-treated or not with the generic Hif activator dimethyloxaloylglycine (DMOG) (25) . In both saline and ITPP treated tumors, DMOG promoted all parameters positively related to the hypoxic response. Vice versa, ITPP antagonized these changes in vehicle-or DMOGexposed tumors. Notably, ITPP effects appeared to be neutralized by the addition of DMOG (Fig. 4A-C (Fig. 4D) . We conclude that the inhibition of Hifs is a main action mechanism underlying the anti-cancerous properties of ITPP.
Direct effects of hypoxia and ITPP on cancer cells
ITPP might modulate Hifs via hypoxia-independent mechanisms. To clarify, we exposed hypoxic MC-38 and CT-26 cultures to normoxia and examined aspects of the hypoxic response.
Similar to ITPP in vivo, normoxia in vitro reduced growth, counteracted the Warburg effect (increased mitochondrial, reduced glycolytic activity), and inhibited invasiveness of cancer cells ( Supplementary Fig. 5A-C) . In contrast, the addition of ITPP to hypoxic cultures had no impact on investigated parameters ( Supplementary Fig. 5D-F) . Therefore, the ITPP effects on tumors are indirect, can be mimicked through normoxia, are dependent on Hif inhibition, and consequently must be mediated by the inhibition of hypoxia.
Impact of ITPP on tumor-associated vascular normalization
ITPP downregulates angiogenic molecules, including Vegf and Plgf (5, 24, 26) ( Therefore, ITPP treatment of tumors is associated with vascular normalization.
Long-term impact of ITPP on the hypoxic tumor response
The observed endothelial changes are consistent with a functional vascular normalization through ITPP, as has been reported for other preclinical models (15, 16 Supplementary Fig. 8A ), indicating a long-range stalling of the hypoxic response through ITPP. Re-examination of endothelial proteins indicated the persistence of a reduced Cd31/34-microvessel density along with an increase in mature vessels at four weeks after ITPP treatment (Fig. 5B, Supplementary Fig. 8B ). We conclude that ITPP induces a stable, longlasting tumor response which is accompanied by vascular normalization.
Impact of ITPP on cytotoxic chemotherapy in comparison to anti-angiogenic therapy
The ITPP effects on tumor-associated vasculature are expected to improve the delivery and efficacy of cytotoxic regimens (16) . The FOLFOX regimen is a standard for metastatic CRC, and nowadays often is combined with antiangiogenic VEGF antibody (32) (33) (34) When assessing tumor load, only small differences were noted between the different treatments regarding tumor volume (Fig. 6B/C) . ITPP alone or with FOLFOX however had the strongest impact on tumor multiplicity, an effect that persisted until death. Altogether, these findings demonstrate a marked potency of ITPP to enhance classic chemotherapy well beyond the efficacy of standard-of-care treatments.
Discussion
In this study, we demonstrate that the effects of ITPP on experimental liver metastases rely antiangiogenic therapy has its conceptual limitations (i.e. enhancement of hypoxia, targeting of only one aspect of the hypoxic response) and is suspected to increase metastatic risk (37, 38) , perhaps explaining its small impact on overall survival (5, (32) (33) (34) . By inhibiting the hypoxic response through normoxic restoration, ITPP should be largely devoid of such risks.
A potential danger however may be ITPP administration at too wide intervals. Such application could lead to fluctuations in tissue O 2 -levels as is known from intermittent hypoxia, thought to be an even stronger driver of malignancy than chronic hypoxia (39) . Notably, sufficient provision of ITPP over longer periods seems feasible. Given that ITPP acts in an untargeted, systemic way, the risk of resistance development likely is small compared to targeted agents (40, 41) . More importantly, ITPP has not been associated with toxicity thus far.
In all animals studies including ours, ITPP was very well tolerated (13) (14) (15) 42) , and no impact on hematological parameters has been reported (13) . Minor in vitro toxicity was noted, however only at doses ~30x higher than we used (16) 
